Radiopharm shares surge 15.81% premarket after approval to initiate Phase 1 trial of RAD 402 in prostate cancer.

Radiopharm Theranostics (RADX) surged 15.81% in premarket trading following the announcement that it received approval to initiate a Phase 1 therapeutic trial of RAD 402 (KLK3-mAb with Tb161) in advanced prostate cancer. This regulatory milestone, reported by GlobeNewswire three days prior, marks a critical step in the development of the company’s targeted radiopharmaceutical candidate, signaling progress in its oncology pipeline and enhancing investor confidence in its therapeutic innovation potential. The approval aligns with the company’s focus on advancing precision medicine for cancer treatment, reinforcing optimism about future clinical and commercial opportunities.